New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
08:03 EDTRWEOY, COP, BP, CVX, NDAQ, XOM, TOT, RDS.AEnergy firms join Nasdaq in arguing against EU collateral requirements, WSJ says
Organizations representing Europe's biggest electricity and gas producers, including Exxon Mobil (XOM), Royal Dutch Shell (RDS.A), RWE AG (RWEOY) and others, have joined Nasdaq (NDAQ) in arguing to the European Commission that tougher proposed requirements on the type of collateral that must be posted to trade energy derivatives will be prohibitively expensive, reported The Wall Street Journal. Other publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), and Total (TOT). Reference Link
News For A;NDAQ;COP;TOT;CVX;RWEOY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 20, 2015
11:13 EDTNDAQNASDAQ management to meet with Jefferies
Subscribe for More Information
07:26 EDTCVX, COPUBS to hold a conference
Subscribe for More Information
May 19, 2015
09:37 EDTCVXActive equity options trading on open
Subscribe for More Information
07:07 EDTNDAQNASDAQ growth initiatives could boost EPS, says Wells Fargo
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
10:01 EDTCVXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:36 EDTCVXActive equity options trading on open
Subscribe for More Information
09:20 EDTCVXW.R. Grace, Chevron JV to build catalysts plant in Lake Charles, LA
Subscribe for More Information
07:56 EDTCVXKosmos provides update on Mauritania drilling
Subscribe for More Information
07:23 EDTCVXChevron downgraded to Sell from Neutral at Goldman
Subscribe for More Information
06:06 EDTCOPConocoPhillips sees holding CapEx flat for next three years, Reuters reports
ConocoPhillips CEO Ryan Lance told Reuters in an interview that the energy company is planning to hold its capital expenditure level over the next three years. The company cut its 2015 capital budget to $11.5B in January due to the oil price drop, but now sees maintaining the CapEx view for three years despite a slight recovery in oil prices. Reference Link
May 15, 2015
09:01 EDTCOPErin Energy receives government approval for license extension in The Gambia
Subscribe for More Information
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
06:44 EDTCVX, COPEnvironmentalists file lawsuit over oil train safety rules, NY Times says
Subscribe for More Information
May 14, 2015
07:51 EDTCOPConocoPhillips management to meet with Deutsche Bank
Meeting to be held in Toronto on May 14 hosted by Deutsche Bank.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use